ppat.1009352.s008.tif (284.44 kB)
Neutralisation of wild-type SARS-CoV-2 by anti-RBD monoclonal antibodies.
figure
posted on 2021-02-26, 18:43 authored by Kuan-Ying A. Huang, Tiong Kit Tan, Ting-Hua Chen, Chung-Guei Huang, Ruth Harvey, Saira Hussain, Cheng-Pin Chen, Adam Harding, Javier Gilbert-Jaramillo, Xu Liu, Michael Knight, Lisa Schimanski, Shin-Ru Shih, Yi-Chun Lin, Chien-Yu Cheng, Shu-Hsing Cheng, Yhu-Chering Huang, Tzou-Yien Lin, Jia-Tsrong Jan, Che Ma, William James, Rodney S. Daniels, John W. McCauley, Pramila Rijal, Alain R. TownsendNeutralisation assays were performed on the indicated antibodies according to the fluorescent focus-forming units microneutralisation method (see methods). Data were normalized to control (no antibody) values of foci, and the grey region comprises ± 1 standard deviation the mean control values. Individual points are displayed ± 1 standard deviation of technical, and curves are shown only where the data for a particular antibody fitted the standard dose-response (Hill) equation (n = 3). Partial: MAb neutralises at least ~40% viruses at 100 nM (highest concentration tested). EC50, 50% effective concentration.
(TIF)
History
Usage metrics
Categories
Keywords
3 weeksantibody responseSARS-CoV -2 infectionACE 2-blocking responsePotent humoral responsesCOVID -19 patientscross-inhibiting clustersneutralising antibodiesplasmablast-derived IgGAnti-RBD MAbsplasmablast responses32 anti-spike MAbsvirus spike glycoproteinACE 2non-competing pairsplasmablast responsememory B cellsanti-non-RBD S 1plasmablast-derived MAbsanti-receptor-binding domainACE 2-blocking anti-RBD antibodies
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC